Data and sources

Where these figures come from

Every number on this site traces to a government statistical agency or a public filing. This page sets out which source, measured on what basis, and as at what date — so that any figure can be checked against the body that issued it.

A fixed compilation

This is a snapshot, not a feed. The figures below were compiled as at the dates stated and are not updated, refreshed or maintained. The agencies that publish them continue to revise and extend their series; this site does not follow those revisions. Treat what follows as a point-in-time record, and check anything you intend to rely on against the issuing agency.

India’s pharmaceutical exports

India’s export figures are compiled across a basket of 487 national tariff lines covering finished medicines, bulk drugs and intermediates, vaccines, surgicals and traditional medicine. Two official carriers report this trade in sequence rather than in parallel — the Directorate General of Commercial Intelligence and Statistics, and the pharmaceutical panel published under the Directorate General of Foreign Trade. Neither covers the full period alone, so both are summed. A figure drawn from one carrier in isolation understates the series, in some years severely.

Figure Basis As at
$31.0 billionTotal exports across the 487-line basket, both carriers summed, FY 2025–26April 2025 – March 2026
+124%Growth from $13.83bn in FY 2014–15 to $31.00bn in FY 2025–26Series to June 2026
74.5%Finished formulations as a share of the basket — $23.09bn of $31.00bnFY 2025–26
$4.94 billionBulk drugs and intermediatesFY 2025–26
$1.55 billionVaccinesFY 2025–26
213 destinations176 individually profiled, plus 37 further destinations listed by name and valueFY 2025–26

The five category figures sum to the $31.0 billion total exactly. A residual gap of two destinations exists between the 215 recorded in the underlying series for the year and the 213 presented here; the page total is stated on the basis of the destinations actually listed.

The United States, on two bases

The United States is the largest single destination, and it is the clearest example of why a basis has to be stated. India’s own record shows $9.43 billion to the United States on the 487-line basket for FY 2025–26. The US Census Bureau records $15.06 billion of pharmaceutical imports from India for calendar year 2025. Both are correct. They differ because they measure different periods and different baskets — a fiscal year against a calendar year, and a defined tariff basket against the whole of the pharmaceutical chapter. Neither figure corrects the other, and a page quoting one names which it is using.

Patents

Pharmaceutical patent filings at the Indian Patent Office rose from 7,158 in 2014 to 18,668 in 2024, counted by filing year on the pharmaceutical subset of the register. The figure is specific to that subset: the full register is very much larger and does not reproduce these numbers. Filing data on this site runs to 2025.

The sources themselves

Source Coverage Used for
Directorate General of Commercial Intelligence and StatisticsFY 2014–15 to 2025–26Exports by destination, tariff-line detail, category mix
Directorate General of Foreign Trade — pharmaceutical panelFY 2014–15 to 2025–26The middle years of the export series, where DGCIS does not carry it
US Census BureauCY 2015–2025United States imports from India, partner-side basis
EurostatCY 2015–2025EU member state imports from India
HM Revenue & CustomsCY 2015–2025United Kingdom imports from India
Statistics CanadaCY 2015–2025Canadian imports from India
Reserve Bank of India2011–2026Overseas direct investment; monthly reference rates for currency conversion
US Food and Drug AdministrationRegister as compiledFDA-registered manufacturing facilities in India
Department for Promotion of Industry and Internal TradeCumulative to Q3 FY 2025–26Foreign direct investment in drugs and pharmaceuticals
Indian Patent Office2014–2025Pharmaceutical patent filing trends
Ministry of External Affairs2023 onwardHumanitarian medicine consignments, reported separately from commercial trade

Known limitations

Humanitarian consignments are not trade. Medicines and equipment supplied through the Ministry of External Affairs are recorded separately and are not included in any export total on this site.

Grant dates are sparse. The patent register carries filing dates far more completely than grant dates, so analysis on this site is by filing year. Grant-date analysis is not supportable at scale from this source.

Company and patent records are not joined. Company registration data and patent data are held separately and are not linked; nothing on this site presents them as connected.

Read more about the practice on the about page.